Pegfilgrastim biosimilar - Eurofarma

Drug Profile

Pegfilgrastim biosimilar - Eurofarma

Alternative Names: Peg-filgrastim biosimilar - Eurofarma; Recombinant pegfilgrastim - Eurofarma

Latest Information Update: 14 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Eurofarma
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Neutropenia

Most Recent Events

  • 01 Nov 2016 Eurofarma Laboratorios completes a phase I trial in Neutropenia (In volunteers) (NCT02589301)
  • 20 Oct 2015 Eurofarma plans a phase I trial in Healthy volunteers in Brazil (NCT02589301)
  • 22 Oct 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top